Nikao

Nikao is a biotechnology company focused on developing precision therapies for mitochondrial diseases by targeting mutated mitochondrial DNA (mtDNA). The company's platform utilizes mitochondrial-targeted nucleases to selectively eliminate pathogenic mtDNA mutations while preserving healthy mitochondrial genomes, thereby restoring cellular energy function. Spun out from the University of Queensland, the Garvan Institute, and the University of Cambridge, Nikao aims to address the root cause of primary mitochondrial diseases such as MELAS and Leigh syndrome. Their approach represents a significant advancement in mitochondrial medicine, offering potential cures for conditions that currently have limited treatment options. By leveraging world-class expertise in mitochondrial biology, Nikao is positioned to lead the development of next-generation genetic medicines for metabolic and age-related disorders.